Szabolcs Lehel

TL;DR: The synthesis, chiral separation, and pharmacological profiling of two possible PET candidates toward a wide selection of CNS-targets are detailed and it is shown that neither of the radioligands could be displaced by the 5-HT7 receptor selective inverse agonist SB-269970.

TL;DR: Comparing 15 migraine patients and 16 controls, it is found that migraine patients have significantly lower neocortical 5-HT4 receptor binding than controls, which is in contrast with the current belief that migraine is associated with low brain 5- HT levels.

TL;DR: It is shown that small polar radiometabolites can substantially decrease the signal-to- Background ratio of PET radioligands for neuroimaging, and it is found that [11C]Cimbi-36 has a better signal- to-background ratio, and thus will be more sensitive to changes in 5-HT2A receptor levels in the brain.

TL;DR: The design, synthesis, and pharmacological evaluation of a set of compounds structurally related to the high affinity serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (6, LP-211) are described.

TL;DR: It is indicated that met-carriers have increased subcortical 5-HTT binding, adding to emerging evidence that BDNF val66met contributes to differences in the human brain serotonin system, informing how variability in the 5- HTT level emerges and may represent an important molecular mediator of BDNFval66met effects on behavior.